| 摘要 |
The invention relates to the chemical and pharmaceutical industry and to medicine and specifically concerns methods for treating acute cerebral and spinal blood flow disorders. The treatment method comprises administering a pharmaceutical composition comprising, as a biologically active substance, a protein-polypeptide complex, and pharmaceutically acceptable auxiliary additives, including a pharmaceutically acceptable diluent comprising a pharmacopoeial buffer solution, high-molecular-weight substances, stabilizers, preservatives and solubilizers. The pharmaceutical composition is administered in a concentration of 0.05-0.8 mg/day subcutaneously, intramuscularly, intravenously, intranasally or intrathecally. The protein-polypeptide complex included in the pharmaceutical composition as the biologically active substance (pharmacological substance) is produced from the embryonic brain of agricultural ungulates in the period of gestation, from the middle of the first trimester of pregnancy to the middle of the final trimester of pregnancy and comprises negatively charged, weakly acid, neutral proteins and polypeptides relating to growth and differentiation factors, to signal molecules and to molecules of intercellular adhesion, with molecular masses of from 5 to 200 kDa, wherein a minimum of 80% of the general mass of the protein has a molecular mass of from 10 to 120 kDa. |
